Aleve Ads Cite Specific FDA Advisory Panel Opinions On Naproxen Safety
This article was originally published in The Pink Sheet Daily
Bayer steers clear of directly implying FDA endorsement of naproxen's safety by referencing mainstream media reports on the committees' discussions about COX-2 inhibitors and NSAIDs.
You may also be interested in...
An AstraZeneca “patient safety” print ad that ran in mid-November “misleadingly suggests that the agency does not believe that Crestor poses safety concerns,” the FDA ad division says in an “untitled” letter to the company. The Crestor ad asserted FDA has concluded safety concerns about rosuvastatin “have no medical or scientific basis.”
Panel review provides examples of different attitudes toward switches between OTC experts, other category-specific prescribers.
Downey says Rx sales of approximately $20 mil. have restricted availability of the emergency contraceptive at pharmacies across the country.